Dulaglutide (Trulicity) studies: 418 papers with results
Page 9 of 9
- Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
Samuels JM · Diabetes, obesity & metabolism · 2024
Not a test of Dulaglutide (Trulicity) alone · 6 results
- Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases.
Ren H · Nano letters · 2025
Not a test of Dulaglutide (Trulicity) alone · 2 results
- A retrospective, single-center cohort study on complications after dental extractions in patients taking biologic agents.
Davila A · Journal of the American Dental Association (1939) · 2022
Not a test of Dulaglutide (Trulicity) alone · 2 results
- Glucagon-like peptide-1 receptor agonists and risk of osteoarthritis among individuals with type 2 diabetes: A population-based cohort study.
Jeon M · Diabetes research and clinical practice · 2026
Not a test of Dulaglutide (Trulicity) alone · 2 results
- Comprehensive pharmacovigilance assessment of pairwise drug-drug interactions and acute pancreatitis in the FDA adverse event reporting system: focus on incretin-based drugs.
Kazume I · Frontiers in drug safety and regulation · 2026
Not a test of Dulaglutide (Trulicity) alone · 2 results
- Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.
Ren L · Diabetes, obesity & metabolism · 2026
Not a test of Dulaglutide (Trulicity) alone · 8 results
- Effectiveness for adding or switching from other incretin-related drugs to oral semaglutide in type 2 diabetes.
Oya J · Journal of diabetes investigation · 2025
Not a test of Dulaglutide (Trulicity) alone · 11 results
- Higher Compliance with Treatment Administration Instructions for Injectable Dulaglutide versus Oral Semaglutide Reported by People with Type 2 Diabetes in Clinical Practice Settings in Spain: The TRU-Experience Study.
Díaz-Cerezo S · Patient preference and adherence · 2025
Not a test of Dulaglutide (Trulicity) alone · 4 results
- Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting.
Hu Y · Annals of translational medicine · 2022
Not a test of Dulaglutide (Trulicity) alone · 5 results
- Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations.
Skrivanek Z · Journal of diabetes science and technology · 2012
Not a test of Dulaglutide (Trulicity) alone · 1 result
- Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
Feng Z · Frontiers in pharmacology · 2023
Not a test of Dulaglutide (Trulicity) alone · 11 results
- Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis.
Nomoto H · Pharmaceutics · 2023
Not a test of Dulaglutide (Trulicity) alone · 7 results
- Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice.
Kubota-Okamoto S · Journal of diabetes investigation · 2026
Not a test of Dulaglutide (Trulicity) alone · 1 result
- Glucagon-like Peptide-1 receptor agonist use is not associated with increased reoperation risk following rotator cuff repair.
Rasmussen ST · Journal of orthopaedics · 2025
Not a test of Dulaglutide (Trulicity) alone · 3 results
- Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.
Bu F · Journal of the American College of Cardiology · 2026
Not a test of Dulaglutide (Trulicity) alone · 7 results
- Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database.
Anatriello A · Pharmacological reports : PR · 2026
Not a test of Dulaglutide (Trulicity) alone · 6 results
- [An elderly patient with type 2 diabetes who developed a hyperglycemic emergency and showed a marked decline in insulin secretion, but she was able to be weaned off insulin by alleviating glucose toxicity and adjusting her medication: A case report].
Ohashi Y · Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics · 2026
Not a test of Dulaglutide (Trulicity) alone · 1 result
- Benchmarking the medication efficiency and technological progress of diabetes drugs.
Zhang H · Frontiers in public health · 2024
Not a test of Dulaglutide (Trulicity) alone · 4 results